The name "acid phosphatase" refers not to a single protein but to a family of phosphohydrolases that share one defining feature: optimal catalytic activity in an acidic environment, typically at pH 4–6, where they cleave phosphate monoesters from a broad range of substrates. At least five human isoenzymes — conventionally designated ACP1 through ACP5, plus additional lipid-specific members such as ACP6 — differ markedly in cellular localization, substrate preference, and tartrate sensitivity, which is why a single "acid phosphatase level" in a report can mean very different things depending on the assay and the clinical context. Historically the term described a total serum enzymatic activity measured with chromogenic substrates such as p-nitrophenyl phosphate; today, where the marker is still used, it is almost always the isoform-specific signal — prostatic acid phosphatase or tartrate-resistant acid phosphatase 5b — that carries the diagnostic weight. The enzyme's utility has shifted from a once-routine oncology screen to a set of focused, high-value applications in bone metabolism, hematopathology, and lysosomal storage disease.

Measuring these isoforms reliably requires reagents matched to the question being asked. Our portfolio covers isoform-specific ELISA kits for prostatic acid phosphatase and tartrate-resistant acid phosphatase 5b, matched antibody pairs for custom immunoassay development, and colorimetric activity-assay components (substrate, tartrate inhibitor, and standards) for total acid phosphatase and for differentiating tartrate-resistant from tartrate-inhibitable fractions. For laboratories quantifying the cytosolic low-molecular-weight tyrosine phosphatase (ACP1) or the lysosomal isoform (ACP2), we provide validated capture and detection antibodies optimized to avoid the cross-reactivity that plagues polyclonal anti-ACP reagents across this conserved family.

Browse More ACP Products

The Acid Phosphatase Isoenzyme Family

The human ACP family is best understood as a set of structurally related but functionally distinct enzymes encoded by separate genes. What unites them is the catalytic signature — hydrolysis of phosphate monoesters at acidic pH — and what separates them is everything that matters for diagnosis: cellular localization, substrate preference, and, above all, tartrate sensitivity. Most acid phosphatases are inhibited by L-(+)-tartrate, whereas ACP5 is not, which is the origin of the term "tartrate-resistant." Historically, total acid phosphatase activity was measured and the tartrate-resistant fraction subtracted to isolate the prostatic and lysosomal component; today isoform-specific immunoassays have largely replaced that subtraction because they avoid the hemolysis and substrate-artifact problems of the enzymatic test. The distinction remains conceptually essential: a "high acid phosphatase" report may denote total enzymatic activity, prostatic acid phosphatase, or other isoforms — answers to entirely different clinical questions. The five classic members are introduced individually below, each as a distinct entity for which assay-specific reagents can be matched.

ACP1 — Cytosolic Low-Molecular-Weight Tyrosine Phosphatase

ACP1, also called the low-molecular-weight protein tyrosine phosphatase (~18 kDa), is a cytosolic enzyme that functions primarily as a protein tyrosine phosphatase rather than a classical phosphomonoesterase. It fine-tunes the phosphorylation state of receptor tyrosine kinases and adhesion complexes, and its activity is redox-sensitive — oxidation switches it off, tying it to the cellular redox state. Polymorphisms at the ACP1 locus have been associated in research with psychiatric phenotypes, including suicidality risk, and with cardiovascular outcomes in rheumatoid arthritis. It is the member least like a "classical" acid phosphatase in routine diagnostics but a frequent target in signaling and oncology research, where isoform-specific antibodies and activity reagents are used to separate its function from that of the secreted phosphatases.

ACP2 — The Lysosomal Isoform

ACP2 is the lysosomal acid phosphatase, broadly expressed across tissues, where it dephosphorylates mannose-6-phosphate–tagged proteins as they arrive at the lysosome and helps process the incoming enzyme cargo. Because it is widespread and tartrate-sensitive, it contributes substantially to the "tartrate-inhibitable" fraction of a total serum activity assay. It is rarely measured as a standalone clinical marker but is relevant in lysosomal-trafficking and storage contexts, and it must be carefully distinguished from prostatic acid phosphatase in any immunoassay because of the high sequence conservation between the two isoforms, which otherwise produces silent cross-reactivity.

ACP3 — Prostatic Acid Phosphatase

ACP3, or prostatic acid phosphatase, is the best-known member and the one that gives the family its historical clinical weight. Synthesized by prostatic epithelium, it also carries tyrosine- and lipid-phosphatase activities. It was the first clinically useful serum tumor marker for prostate cancer and, although superseded by prostate-specific antigen for screening, it retains adjunctive and post-therapy value. Its intracellular form acts as a tumor suppressor while secreted forms behave as a circulating antigen — a duality that shapes both its biomarker interpretation and its emerging role as an immunotherapy target. Its clinical story is covered in full in the dedicated section below.

ACP5 — Tartrate-Resistant Acid Phosphatase 5b

ACP5 encodes tartrate-resistant acid phosphatase, and its 5b isoform — released by osteoclasts during bone resorption — is now the most widely used acid phosphatase assay in bone disease. Unlike the other isoforms it is not inhibited by tartrate, and it is cleared by the liver rather than the kidney, giving it renal independence and making it robust in chronic kidney disease and hemodialysis. The osteoblast-derived 5a isoform, by contrast, is macrophage-derived and is not a bone-resorption marker. Its clinical applications are detailed in the dedicated section below.

ACP6 — Lysophosphatidic Acid Phosphatase

ACP6 is the least characterized routine-diagnostic member, acting on lipid rather than phosphoprotein substrates as a lysophosphatidic acid phosphatase. It rounds out the family as a structurally related but functionally distinct enzyme and is generally of interest in lipid-signaling and metabolic research rather than in the standard clinical acid phosphatase workup. Validated capture and detection reagents are available for each of the five isoforms above, allowing a single study to profile the whole family without changing platforms.

Prostatic Acid Phosphatase: From First Tumor Marker to Immunotherapy Antigen

Prostatic acid phosphatase holds a specific place in diagnostic history as the first clinically useful serum tumor marker, introduced in the 1940s–50s for prostate cancer. Its limitations became clear once prostate-specific antigen entered routine use in the 1980s: prostatic acid phosphatase is less sensitive for early and localized disease, and — critically — it is not prostate-specific. It is expressed by melanoma, testicular germ-cell tumors, urothelial carcinoma, and other malignancies, and its serum level rises with benign prostatic hyperplasia, prostatitis, prostatic infarction, and any mechanical manipulation of the gland. Current test-utilization guidance therefore discourages prostatic acid phosphatase for primary screening and frames it strictly as an adjunct interpreted alongside prostate-specific antigen. One genuine residual value is in post-therapy monitoring: levels normalize after successful treatment, and recurrence or residual disease is associated with re-elevation, so serial measurements can flag biochemical relapse in cases where prostate-specific antigen alone is ambiguous.

A second life for prostatic acid phosphatase has opened in immuno-oncology. Because the protein is expressed in more than 95% of prostate cancers — including tumors that have lost prostate-specific membrane antigen expression — it is an attractive target for T-cell–based therapies. An autologous cellular immunotherapy built on a recombinant prostatic acid phosphatase–GM-CSF fusion protein demonstrated a statistically significant survival advantage in asymptomatic metastatic castration-resistant prostate cancer in pivotal trials, validating the antigen as therapeutically actionable. Beyond that, research has shown that the intracellular form of the enzyme acts as a tumor suppressor in prostate epithelium by dephosphorylating the oncoprotein ErbB2, while secreted forms may modulate pain pathways — findings that explain why the protein's loss during cancer progression complicates its use as a simple quantitative biomarker. These dual functions are precisely why modern assay design distinguishes the intracellular (growth-regulatory) from the secreted (circulating) form rather than reporting "total PAP" as a single number.

Figure 1. Association of cPAcP and ErbB-2 phosphorylation levels in androgen-sensitive LNCaP C-33 and androgen-independent LNCaP C-81 and PC-3 cells. (Source: Muniyan S, et al. 2013)

Measurement Considerations: Activity Assay vs Isoform ELISA

Practical assay note: Before ordering or interpreting any "acid phosphatase" result, confirm which assay was used. A total enzymatic activity test (p-nitrophenyl phosphate substrate, with and without tartrate) reports units of hydrolysis and is vulnerable to hemolysis, platelet release, and anticoagulant effects — EDTA plasma is preferred over serum for activity assays because clotting activates platelets that secrete phosphatase. An isoform-specific ELISA for prostatic acid phosphatase or TRAP5b reports a mass or activity concentration of one protein and is unaffected by the tartrate distinction. TRAP5b ELISA requires distinguishing 5a from 5b; the two commercial platforms achieve this differently (activity-substrate specificity versus capture of the active osteoclast isoform), so values are not directly interchangeable and a single reference range cannot be assumed across methods.

For prostatic acid phosphatase specifically, pre-analytical confounders dominate interpretation: recent digital rectal examination, biopsy, catheterization, or ejaculation can transiently raise levels, so sampling should follow a quiet interval. Benign prostatic hyperplasia and prostatitis also elevate the marker, so an isolated high value is never diagnostic. In bone studies, the key comparator is β-CTX: if renal function is reduced, β-CTX loses specificity while TRAP5b does not, so pairing the two actually helps separate true high turnover from renal artifact. Laboratories developing in-house immunoassays should validate antibody specificity against recombinant ACP family members, because the high sequence conservation across isoforms — especially between prostatic acid phosphatase and ACP2 — produces cross-reactivity that silently inflates apparent concentrations.